Tech Company Financing Transactions
Emalex Biosciences Funding Round
Paragon Biosciences, Fidelity Management & Research Company and Valor Equity Partners participated in a $35 million Series C funding round for Emalex Biosciences. The round was recorded on 3/24/2021.
Transaction Overview
Company Name
Announced On
3/24/2021
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to continue to develop its critical work as it pursues an effective drug therapy for people living with Tourette syndrome and childhood-onset fluency disorder (stuttering)--two conditions with high unmet needs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
330 N. Wabash 3500
Chicago, IL 60611
USA
Chicago, IL 60611
USA
Phone
Undisclosed
Website
Email Address
Overview
Emalex is committed to addressing unmet medical needs by developing novel treatments for central nervous system movement disorders and fluency disorders. We partner with patient advocacy organizations to raise awareness of these disorders and support their education outreach and communication efforts.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Aronin
Vice President
Atul Mahableshwarkar
VP - Bus. Development
Eric Messner
VP - Manufacturing
Jay White
VP - Operations
David Kim
VP - R & D
Timothy Cunniff
VP - R & D
Stephen Wanaski
VP - Regulatory Affairs
Jenny Swalec
Browse more venture capital transactions:
Prev: 3/24/2021: Eat Just venture capital transaction
Next: 3/24/2021: Ro venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs